Technology and Platform

CytoLynx focuses on iPSC-NK cell biology and applies precision gene editing technique to iPSCs to develop the safest, most effective, most clinically-applicable cell therapy for cancer immunotherapy. Multi-valent engager using a proprietary Flex-NK™ technology has been customized to engage and activate NK cells at the tumor site. CytoLynx iPSC-NK therapy offers a curable optionality to cancer patients.